Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
4.450
-0.250 (-5.32%)
Mar 31, 2025, 10:52 AM EDT - Market open
Precision BioSciences Employees
Precision BioSciences had 109 employees as of December 31, 2023. The number of employees decreased by 89 or -44.95% compared to the previous year.
Employees
109
Change (1Y)
-89
Growth (1Y)
-44.95%
Revenue / Employee
$630,239
Profits / Employee
$65,752
Market Cap
46.64M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
DTIL News
- 5 days ago - Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - Business Wire
- 10 days ago - Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - Business Wire
- 11 days ago - Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 - Business Wire
- 12 days ago - Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Business Wire
- 14 days ago - Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B - Business Wire
- 19 days ago - iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting - Business Wire
- 5 weeks ago - Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Business Wire
- 5 weeks ago - Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate - Benzinga